This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Spector, J. I. Articles by Creed, M. R. Search for Related Content PubMed PubMed Citation Articles by Spector, J. I. Articles by Creed, M. R.

A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy

^a Berkshire Hematology/Oncology, PC, Pittsfield, Massachusetts; ^b Lakeland Medical Center, St. Joseph, Michigan; ^c St. Elizabeth Hospital, Youngstown, Ohio; ^d Fort Wayne Medical Oncology/Hematology Inc., Fort Wayne, Indiana; ^e SORRA Research Center, Inc., Birmingham, labama; ^f West Paces Clinical Research, Atlanta, Georgia; ^g University Medical Center, Stony Brook, New York; ^h Northern New Jersey Cancer Center, Hackensack, New Jersey; ⁱ Carolina Gynecological Oncology, Winston-Salem, North Carolina; ^j Arcadia, California; ^k Mountain States Tumor Institute, Boise, Idaho; ^l Pacific Shores Medical Group, Long Beach, California; ^m Glaxo Wellcome Inc., Research Triangle Park, North Carolina, USA

Correspondence: Mary R. Creed, M.S.N., Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709-3398, USA. Telephone: 919-483-5196; Fax: 919-483-0103; e-mail: mrc7253{at}glaxowellcome.com

Purpose: To compare the efficacy and safety of oral ondansetron with i.v. granisetron each given as a single dose prior to administration of highly emetogenic cisplatin chemotherapy.

Patients and Methods: Chemotherapy-naive patients with histologically confirmed malignancies were randomized to receive a single 24 mg ondansetron hydrochloride tablet plus a 50 ml i.v. infusion of normal saline, or a single 10 µg/kg (50 ml) i.v. infusion of granisetron plus a placebo tablet in this multicenter, double-blind, parallel-group trial. Study drug was administered 30 min prior to a single i.v. infusion of cisplatin (50-75 mg/m²), given over a period of three h. Concurrent administration of corticosteroids was not allowed. Efficacy measurements included the number of emetic episodes, need for rescue medication, and patient assessments of nausea and appetite. Complete response (CR) was defined as no emetic episodes, rescue, or withdrawal; major response was defined as one or two episodes. Safety was evaluated by monitoring adverse events and changes in laboratory parameters.

Results: A total of 371 patients entered the study and received study drug, of whom 184 received ondansetron and 187 received granisetron. For all parameters tested, a single 24 mg oral ondansetron tablet was at least as effective as i.v. granisetron. CR was achieved in 58% of ondansetron-treated patients and 51% of granisetron-treated patients (95% confidence interval on the difference: -4% to 17%). Subjective assessments revealed no difference with regard to complete control of nausea, appetite, or satisfaction with antiemetic therapy. Both drugs were well tolerated; the most common adverse event was headache.

Conclusion: A single 24 mg oral dose of ondansetron is at least as safe and effective as a single i.v. infusion of 10 µg/kg of granisetron in preventing nausea and vomiting induced by highly emetogenic cisplatin chemotherapy.

Key Words. Cisplatin • Chemotherapy • Antiemetics • Ondansetron • Granisetron • Vomiting • Nausea